Your browser doesn't support javascript.
loading
Genomic Breakpoints' Characterization of a Large CHEK2 Duplication in an Italian Family with Hereditary Breast Cancer.
Germani, Aldo; Guadagnolo, Daniele; Salvati, Valentina; Micolonghi, Caterina; Mancini, Rita; Mastromoro, Gioia; Sadeghi, Soha; Petrucci, Simona; Pizzuti, Antonio; Piane, Maria.
Afiliação
  • Germani A; Department of Clinical and Molecular Medicine, Sapienza University of Rome, 00185 Rome, RM, Italy.
  • Guadagnolo D; Department of Experimental Medicine, Sapienza University of Rome, 00185 Rome, RM, Italy.
  • Salvati V; Scientific Direction, IRCCS Regina Elena National Cancer Institute, 00128 Rome, RM, Italy.
  • Micolonghi C; Department of Experimental Medicine, Sapienza University of Rome, 00185 Rome, RM, Italy.
  • Mancini R; Department of Clinical and Molecular Medicine, Sapienza University of Rome, 00185 Rome, RM, Italy.
  • Mastromoro G; S. Andrea University Hospital, 00189 Rome, RM, Italy.
  • Sadeghi S; Department of Experimental Medicine, Sapienza University of Rome, 00185 Rome, RM, Italy.
  • Petrucci S; Department of Experimental Medicine, Sapienza University of Rome, 00185 Rome, RM, Italy.
  • Pizzuti A; Department of Clinical and Molecular Medicine, Sapienza University of Rome, 00185 Rome, RM, Italy.
  • Piane M; S. Andrea University Hospital, 00189 Rome, RM, Italy.
Diagnostics (Basel) ; 12(7)2022 Jun 22.
Article em En | MEDLINE | ID: mdl-35885426
ABSTRACT
CHEK2 (checkpoint kinase 2; MIM# 604373) is a tumor suppressor gene that encodes a serine threonine kinase involved in pathways such as DNA repair, cell cycle arrest, mitosis, and apoptosis. Pathogenic variants in CHEK2 contribute to a moderately increased risk of breast and other cancers. Several variant classes have been reported, either point mutations or large intragenic rearrangements. However, a significant portion of reported variants has an uncertain clinical significance. We report an intragenic CHEK2 duplication, ranging from intron 5 to intron 13, identified in an Italian family with hereditary breast cancer. Using long range PCR, with duplication-specific primers, we were able to ascertain the genomic breakpoint. We also performed a real-time PCR to assess a possible loss-of-function effect. The genomic characterization of large intragenic rearrangements in cancer susceptibility genes is important for the clinical management of the carriers and for a better classification of rare variants. The molecular definition of breakpoints allows for the prediction of the impact of the variant on transcripts and proteins, aiding in its characterization and clinical classification.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Diagnostics (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Diagnostics (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália